ACLX vs. OLMA

Last updated Jun 4, 2026

ACLX (Arcellx Inc) and OLMA (Olema Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. At a 0.23 correlation, their price movements are largely independent.

Performance

ACLX vs. OLMA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arcellx Inc (ACLX) and Olema Pharmaceuticals, Inc. (OLMA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

ACLX

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

OLMA

• 1D: -1.68%
• 1M: -28.16%
• YTD: -57.96%
• 6M: -61.43%
• 1Y: 159.51%
• 3Y*: 22.84%
• 5Y*: -17.63%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

ACLX vs. OLMA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
ACLX Arcellx Inc	76.49%	-14.98%	38.18%	79.15%	84.40%
OLMA Olema Pharmaceuticals, Inc.	-57.96%	328.82%	-58.45%	472.65%	-58.33%

Correlation

The correlation between ACLX and OLMA is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.25
Correlation (3Y) Calculated over the trailing 3-year period	0.27
Correlation (All Time) Calculated using the full available price history since Feb 7, 2022	0.23

Fundamentals

EPS ACLX : -$3.86 OLMA : -$2.03
Total Revenue (TTM) ACLX : $35.90M OLMA : $0.00
Gross Profit (TTM) ACLX : $810.00K OLMA : -$187.00K
EBITDA (TTM) ACLX : -$209.52M OLMA : -$197.79M

Return for Risk

ACLX vs. OLMA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

OLMA

OLMA Risk / Return Rank: 80
OLMA Sharpe Ratio Rank: 71
OLMA Sortino Ratio Rank: 91
OLMA Omega Ratio Rank: 89
OLMA Calmar Ratio Rank: 77
OLMA Martin Ratio Rank: 74

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ACLX vs. OLMA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Arcellx Inc (ACLX) and Olema Pharmaceuticals, Inc. (OLMA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	ACLX	OLMA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	1.00	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.16	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	-0.23	—

Drawdowns

Drawdown Indicators

	ACLX	OLMA	Difference
Max Drawdown Largest peak-to-trough decline	—	-96.26%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-70.67%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-82.15%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-93.36%	—
Current Drawdown Current decline from peak	—	-80.72%	—
Average Drawdown Average peak-to-trough decline	—	-74.98%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	33.14%	—

Volatility

Volatility by Period

	ACLX	OLMA	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	21.66%	—
Volatility (6M) Calculated over the trailing 6-month period	—	55.93%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	160.52%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	107.97%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	106.41%	—

Dividends

ACLX vs. OLMA - Dividend Comparison

Neither ACLX nor OLMA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both ACLX and OLMA in my portfolio?

ACLX and OLMA have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.